down arrow

PDS Biotechnology Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US70465T1079
USD
0.89
0.13 (16.48%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.860.94

52 Week

0.702.28
Valuation
Technical
Day's Volume

CASH

613.72 k

Shareholding (Mar 2025)

FII

1.84%

Held by 34 FIIs

DII

86.98%

Held by 12 DIIs

Promoter

0.38%

How big is PDS Biotechnology Corp.?

22-Jun-2025

As of Jun 18, PDS Biotechnology Corp. has a market capitalization of 74.05 million and reported net sales of 0.00 million with a net profit of -35.50 million over the last four quarters. The balance sheet shows shareholder's funds of 19.00 million and total assets of 45.36 million.

As of Jun 18, PDS Biotechnology Corp. has a market capitalization of 74.05 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -35.50 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 19.00 million and total assets amounting to 45.36 million.

Read More

What does PDS Biotechnology Corp. do?

22-Jun-2025

PDS Biotechnology Corp. is an immuno-oncology company developing clinical-stage immunotherapies for cancer, classified as a micro-cap with a market cap of $74.05 million and a recent net profit loss of $8 million. The company has no dividend yield and negative return metrics.

Overview:<BR>PDS Biotechnology Corp. is an immuno-oncology company focused on developing clinical-stage immunotherapies for various cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 74.05 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.94<BR>Return on Equity: -158.73%<BR>Price to Book: 3.31<BR><BR>Contact Details:<BR>Address: 25B VREELAND ROAD, FLORHAM PARK NJ: 07932<BR>Tel: 1 908 5173613<BR>Website: https://www.pdsbiotech.com

Read More

Who are in the management team of PDS Biotechnology Corp.?

22-Jun-2025

As of March 2022, the management team of PDS Biotechnology Corp. includes Independent Chairman Mr. Stephen Glover, President and CEO Dr. Frank Bedu-Addo, Directors Dr. Otis Brawley, Dr. Ilian Iliev, and Independent Directors Ms. Kamil Ali-Jackson, Mr. DeLyle Bloomquist, and Mr. Gregory Freitag.

As of March 2022, the management team of PDS Biotechnology Corp. includes the following individuals:<BR><BR>- Mr. Stephen Glover, who serves as the Independent Chairman of the Board.<BR>- Dr. Frank Bedu-Addo, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Otis Brawley, who is a Director.<BR>- Dr. Ilian Iliev, who is also a Director.<BR>- Ms. Kamil Ali-Jackson, who holds the position of Independent Director.<BR>- Mr. DeLyle Bloomquist, who is an Independent Director.<BR>- Mr. Gregory Freitag, who serves as an Independent Director. <BR><BR>This composition reflects a diverse leadership structure within the company.

Read More

Is PDS Biotechnology Corp. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, PDS Biotechnology Corp. is in a bearish trend, with key indicators signaling bearish momentum and a year-to-date return of -29.45%, significantly underperforming the S&P 500's 12.22%.

As of 11 September 2025, the technical trend for PDS Biotechnology Corp. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators such as the daily moving averages and the weekly KST both signaling bearish momentum. Additionally, Bollinger Bands are bearish on both weekly and monthly time frames. The MACD shows a mildly bullish stance on weekly and monthly charts, but this is overshadowed by the overall bearish signals. <BR><BR>In terms of performance, PDS Biotechnology has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -29.45% versus the S&P 500's 12.22%, and a one-year return of -62.54% compared to 17.14% for the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 55 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.84

stock-summary
Return on Equity

-229.34%

stock-summary
Price to Book

3.42

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-9 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-31.22%
0%
-31.22%
6 Months
-41.56%
0%
-41.56%
1 Year
-60.26%
0%
-60.26%
2 Years
-82.97%
0%
-82.97%
3 Years
-90.86%
0%
-90.86%
4 Years
-89.38%
0%
-89.38%
5 Years
-57.42%
0%
-57.42%

PDS Biotechnology Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is PDS Biotechnology Corp. technically bullish or bearish?

As of 11 September 2025, the technical trend for PDS Biotechnology Corp. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators such as the daily moving averages and the weekly KST both signaling bearish momentum. Additionally, Bollinger Bands are bearish on both weekly and monthly time frames. The MACD shows a mildly bullish stance on weekly and monthly charts, but this is overshadowed by the overall bearish signals. In terms of performance, PDS Biotechnology has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -29.45% versus the S&P 500's 12.22%, and a one-year return of -62.54% compared to 17.14% for the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-187.17%
EBIT to Interest (avg)
-16.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.94
Sales to Capital Employed (avg)
0
Tax Ratio
5.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
31.10%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.45
EV to EBIT
-1.59
EV to EBITDA
-1.59
EV to Capital Employed
43.37
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2727.24%
ROE (Latest)
-158.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 20 Schemes (10.79%)

Foreign Institutions

Held by 34 Foreign Institutions (1.84%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -13.25% vs 27.83% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.60",
          "val2": "-8.70",
          "chgp": "12.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.10",
          "val2": "1.20",
          "chgp": "75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.40",
          "val2": "-8.30",
          "chgp": "-13.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.35% vs -4.89% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-36.30",
          "val2": "-43.00",
          "chgp": "15.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.70",
          "val2": "4.20",
          "chgp": "11.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-37.60",
          "val2": "-42.90",
          "chgp": "12.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.60
-8.70
12.64%
Interest
2.10
1.20
75.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-9.40
-8.30
-13.25%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -13.25% vs 27.83% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-36.30
-43.00
15.58%
Interest
4.70
4.20
11.90%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-37.60
-42.90
12.35%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 12.35% vs -4.89% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About PDS Biotechnology Corp. stock-summary
stock-summary
PDS Biotechnology Corp.
Pharmaceuticals & Biotechnology
PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
Company Coordinates stock-summary
Company Details
25B VREELAND ROAD , FLORHAM PARK NJ : 07932
stock-summary
Tel: 1 908 5173613
stock-summary
https://www.pdsbiotech.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."